19
Mar 2026
Study links gut microbiome imbalance to worsening kidney disease
Researchers at UC Davis School of Medicine have uncovered how an imbalanced gut microbiome escalates the production of metabolic byproducts by certain gut bacteria.
Our Pipeline
Our pharmaceutical products (medicines & vaccines) in development are classified into three stages: phase I, phase II and phase III. These studies into the safety and efficacy of investigational products provide data to support applications to regulators for approval.
The content of our development pipeline is updated weekly as new projects progress from research to development and from development to the market.
For obvious competitive reasons, certain projects in pre-clinical development are not disclosed and some project types may not be identified.
This pipeline information was last updated on 13 March, 2026.
MC-CV100 is an inhaled, targeting the SARS-CoV-2 viral genome for the potential treatment and/or prevention of COVID-19.
MC-D101 is a biologic entity being studied for the treatment of cardiovascular disease.
MC-C852 is a chemical entity being studied for the treatment of cancer.
MC-T176 is a large molecule being studied for the treatment of autoimmune diseases.
Unique, disease modifier mechanism of action to prevent and treat mucositis caused by cancer therapy. Strong preclinical evidence that supports the MoA.
Validated and safe API for the treatment of atopic dermatitis and psoriasis using an innovative topical formulation. Clinical PoC results by 2027.
Injectable product with strong nephroprotective activity in animal models. Clinical PoC by 2027.
Herb extract: An allergoid preparation of grass pollen extract for subcutaneous injection.
MC-H19016 aims to treat hemophilia and rare bleeding disorders for subcutaneous injection.
MC-H19018 is a subcutaneously administered, investigational RNAi therapeutic targeting proprotein convertase subtilisin kexin type 9 (PCSK9) in development for the treatment of hypercholesterolemia.
MC-H19021 is a subcutaneously administered, investigational RNAi therapeutic targeting the hepatitis B virus (HBV) genome for the treatment of chronic HBV infection by our collaborators at Vir Biotechnology. ALN-HBV02 is designed to inhibit expression of all HBV proteins, including hepatitis B surface antigen (HBsAg).
Tree extract: A liquid preparation containing tree pollen extract for sublingual use.
MC-0P-23908 aims to repair the mutation in the eye, leading to normal ABCA4 protein which will potentially stop and perhaps reverse the progression of the disease.
MC-K326 aims to treat non-alcoholic steatohepatitis (NASH) for subcutaneous injection.
Clinical stage product with proven safety repositioned to treat aortic aneurism. Very solid preclinical evidence. Clinical PoC in Marfan syndrome patients by 2027
Clinical stage product with proven safety repositioned to treat complement-mediated diseases for subcutaneous injection.
Immunomodulatory naturally occurring blood-protein that induces tolerogenesis in dendritic cells, to treat rheumatoid arthritis, lupus nephritis, IBD and other autoimmune diseases. Preclinical candidate ready to start regulatory development
Peptide with novel, targeted immunomodulatory mechanism of action, superior safety profile over current biologics, and displaying a low manufacturing cost. In vivo evidence in IBD animal model. MC-K341 targets SAA and IL1β. Next relevant value milestone:
Human naturally occurring protein that increases survival and ameliorates behavior and histochemical readouts. Preclinical PoC in ALS model in 2013.
In the current project, it is proposed to study the effect of MC-K330-01 when administered to symptomatic SOD1G93A mice in early stages of illness (from day 50, subcutaneous administration, 3 times per week).
Marginal but not significant efficacy of tested compound was observed with Catwalk gait analysis and NMJ pathology. Other parameters showed no significant effects of the treatment in SOD1G93A.
OBJECT
Previous results showed that, after intraperitoneal administration of 50 ng of MC-K330-01 to no symptomatic mSOD1G93A mice, treated animals resulted in increased survival, delayed onset of disease and improved the general state.In the current project, it is proposed to study the effect of MC-K330-01 when administered to symptomatic SOD1G93A mice in early stages of illness (from day 50, subcutaneous administration, 3 times per week).
CONCLUSIONS
Therapeutic potential of the compound was evaluated in SOD1G93A ALS mouse model. The drug was delivered subcutaneously in postnatal day 50 female/male mice. Behavioral tests (rotarod, catwalk gait and open field analysis system), electromyography, onset of disease, mouse survival, immunohistochemical, histological and NMJ analysis were used to evaluate the effect of treatment in the ALS model.Marginal but not significant efficacy of tested compound was observed with Catwalk gait analysis and NMJ pathology. Other parameters showed no significant effects of the treatment in SOD1G93A.
Disclaimer
The information above reflects Mercury Pharmaceuticals clinical development pipeline and this is not intended for promotional purposes. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued or delayed, or to fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Our pipeline information is usually updated at the end of every week, how ever Mercury Pharmaceuticals assumes no duty to update this information.Last updated: 13 March, 2026.
MERCURY trials
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Cancer
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Neuroscience
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
STAY INFORMED!
19
Mar 2026
Mandated caps reduce insulin out-of-pocket costs among US Medicare beneficiaries
A new analysis led by researchers at the Johns Hopkins Bloomberg School of Public Health finds that out-of-pockets caps on insulin for Medicare Part D beneficiaries have reined in insulin prices.
19
Mar 2026
Balancing sitting and movement may lower the risk for hypertensive disorders of pregnancy
During pregnancy, women can reduce their risk of developing a hypertensive disorder by nearly 30% by limiting sedentary time to no more than eight hours a day and increasing light, everyday physical activity to at least seven hours a day, according to preliminary research presented at the American Heart Association's EPI|Lifestyle Scientific Sessions 2026.
19
Mar 2026
Brain age from sleep patterns may signal future dementia risk
A machine-learning analysis of brain waves recorded during sleep may help identify people at high risk of developing dementia, according to a study led by UC San Francisco and Beth Israel Deaconess Medical Center in Boston.
Why Us?
Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.